儿童药物研发鼓励政策研究

中国药物警戒 ›› 2014, Vol. 11 ›› Issue (12): 746-748.

儿童药物研发鼓励政策研究

许顺贵,刘春光

武警北京市总队医院药剂科，北京100027

收稿日期:2014-07-06 修回日期:2016-02-03 出版日期:2014-12-08 发布日期:2016-03-02
作者简介:许顺贵，男，本科，主管药师，临床药学。

Study on Incentive Policy for Pediatric Drug Research and Development

XU Shun-gui, LIU Chun-guang

Department of Pharmacy, Beijing Armed Police Corps Hospital, Beijing 100027,China

Received:2014-07-06 Revised:2016-02-03 Online:2014-12-08 Published:2016-03-02

摘要/Abstract

摘要： 目的儿童药物缺乏是国内外普遍现象，完善儿童药物研发鼓励政策是解决儿童药物短缺的有效方式，通过儿童药物研发鼓励政策研究，提出适合我国儿童药物研发的鼓励措施。方法检索WHO、欧美等国药品监管官方网站，梳理国外儿童用药鼓励研发的先进做法，分析我国儿科药物研发鼓励现状，并提出建议。结果与结论我国儿童药物研发鼓励政策应建立并完善儿童药物临床试验的法规，促进儿科药物适宜剂型的研发，推动更多儿童药物进入我国基本药物目录，并增进多部门联合协作。

关键词: 儿童药物, 鼓励政策

Abstract: Objective The lack of pediatric drug is a common phenomenon at home and abroad. Improving the incentive policy for pediatric drug is an effective way to solve the shortage of drug for children. In this paper, through the analysis of research and development for the incentive policy of pediatric drug, put forward the incentive mechanism for suitable pediatric drug in China. Methods Search the official websites of WHO, FDA and MHRA, combining with the foreign advanced approaches for development of pediatric drug. And analyze the present situation and the problems in the pediatric drug development to offer proposals. Results and Conclusion We should pay attention to improve the legal framework of clinical trials in children, promote the development of suitable pediatric drug formulations, screen more pediatric drugs into the Essential Medicine List, and strengthen multi-sectoral joint collaboration.

Key words: pediatric drug, incentive policy

中图分类号:

许顺贵,刘春光. 儿童药物研发鼓励政策研究[J]. 中国药物警戒, 2014, 11(12): 746-748.

XU Shun-gui, LIU Chun-guang. Study on Incentive Policy for Pediatric Drug Research and Development[J]. Chinese Journal of Pharmacovigilance, 2014, 11(12): 746-748.

参考文献

[1] WHO. Medicines: medicines for children [EB/OL]. [2010-06-22](2011-04-01).http://www.who.int/mediacentre/factsheets/fs341/en/.
[2] CDC.药物：儿童药物实况报道（第341号）[EB/OL]. (2010-06-26)[2011-07-12]http://www.chinacdc.cn/gwxx/201210/t20121026_71033.htm.
[3] WHO. Essential medicines for children[EB/OL].（2007-07-02）[2008-11-20].http://www.who.int/childmedicines/en/.
[4] WHO.WHOModel lists of Essential Medicines[EB/OL].(2007-10-05)[2013-04-11]http://www.who.int/medicines/publications/essentialmedicines/en/.
[5] WHO.WHO Model Formulary for Children[EB/OL]. (2009-10-05)[2010-09-01]http://www.who.int/childmedicines/en/.
[6] Association of the British Pharmaceutical Industry .Clinical trials and children's medicines [EB/OL]. (2007-08-20) [2008-10-15].http://www.nottingham.ac.uk/news/expertiseguide/areas/c/clinicaltrials,-of-medicines-for-children.aspx.
[7] EC.children's medicines[EB/OL]. (2006-07-05)[2007-11-10].http://ec.europa.eu/health/human-use/paediatric-medicines/index_ en.htm.
[8] Dr Ian Wong,Dimah Sweis. Paediatric Medicines Research in the UK[J].Drug Safety ，2003，26(8)：25. [9] 郑晶心.儿童用英国国家处方集出版[J].国外药讯，2006，2（1）：4.
[10] 国务院妇女儿童工作委员会. 法国开展儿童用药常识[EB/OL].(2002-01-30)[2003-02-10].www.nwccw.gov.cn/html/.
[11] FDA. US case study [EB/OL].(2005-01-05)[2006-06-11].http://www.fda.gov/bbs/topics/NEWS/2005/NEW01280.html.
[12] 丁锦希，邓媚，白庚亮美国儿科用药数据保护制度及其对儿童药物安全的影响分析[J].中国药学杂志,2012,47(10):749.
[13] 王晓玲，郭春彦.儿童用药剂型与规格的国内外现状分析[J].中国药学杂志，2013，48(7):1316.
[14] 杨志敏，张培培.国外儿童药物审评审批管理现状及特点分析[J].中国药学杂志，2012，47(10):745-747.
[15] 杨悦，粟高超.WHO儿童基本药物示范目录与我国基本药物目录中儿童用药的比较研究[J].中国药房，2011,22（32）：2994.